« Back to Record
Citation APA

Fuchs, C. C., Bodoky, G., Ikeda, M., Melichar, B., Nemecek, R., Ohkawa, S., Swieboda-Sadlej, A., Tjulandin, S., Van Cutsem, E., Loberg, R., Haddad, V., Azevedo, S., Gansert, J. J., Bach, B. B., Carrato, A., Okusaka, T., Van Laethem, J.-L., Lipton, L. L., Riess, H., Szczylik, C., Moore, M. J., & Peeters, M. (2015). A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial. Annals of oncology, 26(5), mdv027, 921-927. doi:10.1093/annonc/mdv027


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/205726

Fuchs, C. C., Bodoky, G., Ikeda, M., Melichar, B., Nemecek, R., Ohkawa, S., Swieboda-Sadlej, A., Tjulandin, S., Van Cutsem, E., Loberg, R., Haddad, V., Azevedo, S., Gansert, J. J., Bach, B. B., Carrato, A., Okusaka, T., Van Laethem, J.-L., Lipton, L. L., Riess, H., Szczylik, C., Moore, M. J., & Peeters, M. (2015). A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial. Annals of oncology, 26(5), mdv027, 921-927. doi:10.1093/annonc/mdv027